FDA Warning Letter Puts Abbott's FreeStyle Libre Quality Controls in the Spotlight
Abbott Laboratories faces heightened regulatory scrutiny after the FDA issued a warning letter concerning the accuracy and testing protocols for its widely used FreeStyle Libre continuous glucose monitors, raising questions about the company's quality systems in a key growth market.